GoodRx (NASDAQ:GDRX) Reports Upbeat Q2 CY2026, Stock Soars

How each outlet headlined it

• FinancialContent center

  GoodRx (NASDAQ:GDRX) Reports Upbeat Q2 CY2026, Stock Soars
• StockStory

  Healthcare tech company GoodRx (NASDAQ:GDRX) reported Q2 CY2026 results exceeding the market’s revenue expectations, but sales fell by 1.3% year on year to $200.4 million. The company’s full-year revenue guidance of $797.5 million at the midpoint came in 2.8% above analysts’ estimates. Its non-GAAP profit of $0.08 per share was in line with analysts’ consensus estimates.